Evidence map›Paper›PMID 34142203›Full record

ArticleRheumatology international2021

Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey.

Somy Cherian, Aby Paul, Sakir Ahmed, Bazil Alias, Manesh Manoj, Ansu K Santhosh, Delcey Rachel Varghese, Narayanan Krishnan, Padmanabha Shenoy

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 8 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 8 syntheses or guidelines pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Somy CherianCentre for Arthritis and Rheumatism Excellence (CARE), Nettoor, Kochi, Kerala, 682040, India.ORCID http://orcid.org/0000-0001-6706-7734
Aby PaulCentre for Arthritis and Rheumatism Excellence (CARE), Nettoor, Kochi, Kerala, 682040, India.ORCID http://orcid.org/0000-0001-6821-6156
Sakir AhmedClinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India.ORCID https://orcid.org/0000-0003-4631-311X
Bazil AliasCentre for Arthritis and Rheumatism Excellence (CARE), Nettoor, Kochi, Kerala, 682040, India.ORCID http://orcid.org/0000-0001-7092-4733
Manesh ManojCentre for Arthritis and Rheumatism Excellence (CARE), Nettoor, Kochi, Kerala, 682040, India.ORCID http://orcid.org/0000-0002-4031-136X
Ansu K SanthoshCentre for Arthritis and Rheumatism Excellence (CARE), Nettoor, Kochi, Kerala, 682040, India.ORCID http://orcid.org/0000-0002-4392-6140
Delcey Rachel VargheseCentre for Arthritis and Rheumatism Excellence (CARE), Nettoor, Kochi, Kerala, 682040, India.ORCID https://orcid.org/0000-0001-7733-2060
Narayanan KrishnanCentre for Arthritis and Rheumatism Excellence (CARE), Nettoor, Kochi, Kerala, 682040, India.ORCID http://orcid.org/0000-0003-1096-6290
Padmanabha ShenoyCentre for Arthritis and Rheumatism Excellence (CARE), Nettoor, Kochi, Kerala, 682040, India. drdpshenoy@gmail.com.ORCID http://orcid.org/0000-0002-7666-1361
All India Institute of Medical Sciences Bhubaneswar · INArthritis and Rheumatism Associates · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with rheumatic and musculoskeletal (RMD) diseases may be at higher risks for COVID-19 infection. Data on the safety of the adenoviral vector-borne ChAdOx1 nCoV-19 and the heat-inactivated BBV152 Vaccines in this group are limited. 724 patients with RMD who had received at least one dose of either the ChAdOx1 or the BBV152 were audited to find out post-vaccination adverse effect (AE) or disease flares. The AE rates in patients with autoimmune rheumatic disease (AIRD) were compared with those with non-AIRD RMDs. The mean age of the cohort was 59.9 (± 10.43) years with a female (n = 581; 80.24%) majority. 523 (70.8%) had AIRD. The ChAdOx1 and the BBV152 vaccines were received by 624 (86.18%) and 77 (10.63%), respectively. 23 (3.17%) were unaware of which vaccine they had received. 238 (32.87%) of patients had at least one comorbidity. 436 (60.22%) participants [306 (59.64%) of those with AIRD and 130 (61.61%) with other RMDs] had at least one adverse effect (AE). Four patients reported flare of arthritis that resolved within 5 days. No patient had any severe AE or required hospitalization. All AEs were self-limiting. Both the ChAdOx1 and the BBV152 vaccines appear safe in RMDs. AEs do not differ between patients with AIRD or non-AIRD. This information can help negate vaccine hesitancy amongst all stakeholders.

Indexed as

AutoimmunityAgedChAdOx1 nCoV-19COVID-19 VaccinesCross-Sectional StudiesFemaleHumansImmunocompromised HostImmunosuppressive AgentsMaleMiddle AgedRheumatic DiseasesVaccinationVaccines, InactivatedChAdOx1 nCoV-19COVID-19 VaccinesImmunosuppressive AgentsVaccines, InactivatedAdenoviral vectorAdjuvantAdverse effectsImmunosuppressantsRheumatic diseasesVaccinationVaccine safety

Identifiers

PMID34142203
PMCPMC8211311
OpenAlexW3169946064

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.